Intuitive Surgical (ISRG) | Financial Analysis & Statements
Intuitive Surgical, Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.9B
Gross Profit
1.9B
66.44%
Operating Income
864.3M
30.15%
Net Income
799.5M
27.89%
EPS (Diluted)
$2.21
Balance Sheet Metrics
Total Assets
20.5B
Total Liabilities
2.5B
Shareholders Equity
17.9B
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
793.8M
Free Cash Flow
730.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Intuitive Surgical Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10.1B | 8.4B | 7.1B | 6.2B | 5.7B |
| Cost of Goods Sold | 3.4B | 2.7B | 2.4B | 2.0B | 1.8B |
| Gross Profit | 6.6B | 5.6B | 4.7B | 4.2B | 4.0B |
| Gross Margin % | 66.0% | 67.5% | 66.4% | 67.4% | 69.3% |
| Operating Expenses | |||||
| Research & Development | 1.3B | 1.1B | 998.8M | 879.0M | 671.0M |
| Selling, General & Administrative | 2.4B | 2.1B | 2.0B | 1.7B | 1.5B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 3.7B | 3.3B | 3.0B | 2.6B | 2.1B |
| Operating Income | 2.9B | 2.3B | 1.8B | 1.6B | 1.8B |
| Operating Margin % | 29.3% | 28.1% | 24.8% | 25.3% | 31.9% |
| Non-Operating Items | |||||
| Interest Income | 365.9M | 324.9M | 192.1M | 29.7M | 69.3M |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 3.3B | 2.7B | 2.0B | 1.6B | 1.9B |
| Income Tax | 434.8M | 336.3M | 141.6M | 262.4M | 162.2M |
| Effective Tax Rate % | 13.1% | 12.6% | 7.2% | 16.3% | 8.6% |
| Net Income | 2.9B | 2.3B | 1.8B | 1.3B | 1.7B |
| Net Margin % | 28.6% | 28.0% | 25.5% | 21.6% | 30.3% |
| Key Metrics | |||||
| EBITDA | 3.6B | 2.8B | 2.2B | 1.9B | 2.1B |
| EPS (Basic) | - | $6.54 | $5.12 | $3.72 | $4.79 |
| EPS (Diluted) | - | $6.42 | $5.03 | $3.65 | $4.66 |
| Basic Shares Outstanding | - | 355200000 | 351200000 | 355700000 | 356100000 |
| Diluted Shares Outstanding | - | 355200000 | 351200000 | 355700000 | 356100000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Intuitive Surgical Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 3.4B | 2.0B | 2.8B | 1.6B | 1.3B |
| Short-term Investments | 2.6B | 2.0B | 2.5B | 2.5B | 2.9B |
| Accounts Receivable | 1.5B | 1.2B | 1.1B | 942.1M | 782.7M |
| Inventory | 1.8B | 1.5B | 1.2B | 893.2M | 587.1M |
| Other Current Assets | 376.4M | 253.7M | 176.7M | 168.6M | 133.9M |
| Total Current Assets | 9.8B | 7.1B | 7.9B | 6.3B | 5.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.1B | 1.6B | 1.1B | 806.4M | 616.1M |
| Goodwill | 751.7M | 718.0M | 736.5M | 746.8M | 757.7M |
| Intangible Assets | 11.1M | 23.0M | 39.1M | 49.8M | 70.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.9B | 1.8B | 1.5B | 1.3B | 1.0B |
| Total Non-Current Assets | 10.7B | 11.6B | 7.6B | 6.7B | 7.7B |
| Total Assets | 20.5B | 18.7B | 15.4B | 13.0B | 13.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 255.1M | 193.4M | 188.7M | 147.0M | 121.2M |
| Short-term Debt | - | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 2.0B | 1.7B | 1.7B | 1.4B | 1.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | - | 87.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 225.8M | 175.2M | 106.1M | 110.3M | 100.3M |
| Total Non-Current Liabilities | 510.8M | 468.3M | 385.5M | 439.3M | 453.7M |
| Total Liabilities | 2.5B | 2.2B | 2.0B | 1.9B | 1.6B |
| Equity | |||||
| Common Stock | 400.0K | 400.0K | 400.0K | 400.0K | 400.0K |
| Retained Earnings | 7.0B | 6.8B | 4.7B | 3.5B | 4.8B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 17.9B | 16.5B | 13.4B | 11.1B | 12.0B |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 0 | 0 | 87.0M |
| Working Capital | 7.8B | 5.4B | 6.2B | 4.8B | 4.7B |
Balance Sheet Composition
Intuitive Surgical Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.9B | 2.3B | 1.8B | 1.3B | 1.7B |
| Depreciation & Amortization | 677.1M | 462.0M | 421.8M | 365.8M | 310.2M |
| Stock-Based Compensation | 788.2M | 676.8M | 592.8M | 513.2M | 449.2M |
| Working Capital Changes | -1.1B | -687.5M | -801.8M | -489.9M | -163.2M |
| Operating Cash Flow | 3.3B | 2.7B | 1.8B | 1.6B | 2.3B |
| Investing Activities | |||||
| Capital Expenditures | -539.8M | -1.1B | -1.1B | -532.4M | -339.5M |
| Acquisitions | -13.9M | -1.0M | -8.9M | -12.8M | -22.7M |
| Investment Purchases | -1.2B | -5.1B | -2.2B | -1.4B | -6.5B |
| Investment Sales | 2.4B | 3.0B | 2.9B | 3.3B | 4.4B |
| Investing Cash Flow | 665.8M | -3.3B | -360.1M | 1.4B | -2.5B |
| Financing Activities | |||||
| Share Repurchases | -2.3B | 0 | -416.3M | -2.6B | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -2.7B | -278.5M | -583.9M | -2.8B | -233.5M |
| Free Cash Flow | 2.5B | 1.3B | 749.6M | 958.4M | 1.7B |
| Net Change in Cash | 1.2B | -860.1M | 838.3M | 139.5M | -411.3M |
Cash Flow Trend
Intuitive Surgical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
54.97
Forward P/E
39.49
Price to Book
8.99
Price to Sales
15.93
PEG Ratio
3.30
Profitability Ratios
Profit Margin
28.38%
Operating Margin
30.16%
Return on Equity
16.69%
Return on Assets
9.39%
Financial Health
Current Ratio
4.88
Debt to Equity
0.95
Beta
1.68
Per Share Data
EPS (TTM)
$8.21
Book Value per Share
$50.19
Revenue per Share
$28.20
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ISRG | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
| ResMed | 32.0B | 21.69 | 5.06 | 25.68% | 27.53% | 13.41 |
| West Pharmaceutical | 22.1B | 40.99 | 6.94 | 19.13% | 16.85% | 10.73 |
| Hologic | 17.0B | 31.54 | 3.23 | 10.86% | 13.18% | 48.05 |
Financial data is updated regularly. All figures are in the company's reporting currency.






